Leaders in Pharmaceutical Business Intelligence Group, LLC, Doing Business As LPBI Group, Newton, MA

“Show Thinking” by AI Deep Research: The AI-generated Biography Description of Aviva Lev-Ari, PhD, RN, Founder of PharmaceuticalIntelligence.com by Perplexity.ai and by Google’s Gemini 2.5 Pro (experimental)

Reporter: Aviva Lev-Ari, PhD, RN

ADDED by Aviva Lev-Ari, PhD, RN on 5/2/2025

CV Format – Not by AI

https://www.linkedin.com/in/avivalevari/

Publication List – Not by AI

• Scientific and Medical Affairs Chronological CV
• Technology Executive, Methodology and Decision Scientist, Functional CV
• Contributions to Design of Algorithm-based Decision Support Systems
• Technical Contributions in the Domain of Electronic Commerce Analytics: Aviva Lev-Ari, Ph.D.
• HealthCare Delivery – Long Term Post Acute Care Nursing Management CV
• Editorials & Publications of Articles in e-Books by Leaders in Pharmaceutical Business Intelligence (LPBI) Group: Contributions by Aviva Lev-Ari, PhD, RN
• List of Invited Lectures, 1983 -2004
• List of Publications, 1983 – 2004
• List of Publications, 2006 – Present
• Cardiovascular Diseases and Pharmacological Therapy: Curations, 2006 – 4/2018
• MedTech & Medical Devices for Cardiovascular Repair – Curations
• Stem Cells and Cardiac Repair: Content Curation & Scientific Reporting
• Regulatory Affairs: Publications on FDA-related Issues – Aviva Lev-Ari, PhD, RN
• Cancer Research: Curations and Reporting
• Autobiographical Annotations: Tribute to My Professors
• Public Eulogy of Note: Prof. Allan Pred, University of California, Berkeley
• Public Eulogy of Note: Prof. David Hooson, University of California, Berkeley

 

Updated on 4/30/2025

For a SYNOPSIS by xAI, see

LPBI Group’s Legacy and Biography of Aviva Lev-Ari, PhD, RN, Founder & Director, INTERACTIVE CHAT with Grok, created by xAI

https://pharmaceuticalintelligence.com/2025/04/30/interactive-chat-with-grok-created-by-xai-lpbi-groups-legacy-and-biography-of-aviva-lev-ari-phd-rn-founder-director/

Updated on 4/30/2025

Below, please find Edited and Approved by Aviva Lev-Ari, PhD, RN on 4/29/2025

• Bio Version 1, 4/19/2025, Perplexity.ai

• Bio Version 2, 4/29/2025, Perplexity.ai AND Gemini 2.5 Pro (experimental)

 

Perplexity.ai – my “ask” produced

Bio Version 1, 4/19/2025

https://www.perplexity.ai/search/686cec2f-7a11-4f3d-9c8b-8a5c80f3282a#12

Perplexity.ai BIO Version 1, 4/19/2025

https://www.perplexity.ai/search/686cec2f-7a11-4f3d-9c8b-8a5c80f3282a?12=r

Perplexity.ai suggests answers for AI-created questions:

• What do you know about “Aviva Lev-Ari, PhD, RN”
• Images of “Aviva Lev-Ari, PhD, RN”
• What are some of the most popular articles curated by Aviva Lev-Ari
• What are the most cited articles by Aviva Lev-Ari
• What are the main topics covered in Aviva Lev-Ari’s most cited articles
• How does Aviva Lev-Ari’s work in cancer etiology compare to her work in immunology
• Comparison of Aviva Lev-Ari’s Work in Cancer Etiology vs. Immunology
• What specific areas of cancer etiology has Aviva Lev-Ari focused on
• What are the most recent publications by Aviva Lev-Ari on cancer
• How does Aviva Lev-Ari’s research address the role of genetics in cancer development
• What about her work in Cardiovascular? Books on Amazon?
• How did Aviva Lev-Ari’s background in nursing influence her career in pharmaceutical intelligence
• How did Aviva Lev-Ari’s nursing career prepare her for her role in electronic scientific publishing
• In what ways did Aviva Lev-Ari’s nursing career shape her understanding of healthcare delivery and its application in scientific publishing

Perplexity.ai – Aviva’s “ask” produced

Bio Version 2, 4/29/2025

https://www.perplexity.ai/search/i-wish-to-get-a-description-an-KfyRhnOWSmWDJ3DNGY0MoA?0=d

 

Aviva Lev-Ari, PhD, RN, is a distinguished innovator in electronic scientific publishing, biomedical knowledge curation, and medical education. She is the founder and director of the Leaders in Pharmaceutical Business Intelligence (LPBI) Group, a pioneering organization in digital scientific publishing and medical text analysis14. Her career bridges academia, industry, and healthcare, with significant contributions to knowledge dissemination and the development of new methodologies for scientific curation.

Professional Background

• Founder & Director, LPBI Group: Dr. Lev-Ari established LPBI Group in 2012, initially as an electronic scientific publisher and later evolving it into a platform for medical text analysis using NLP, machine learning, and AI. The group also explores content monetization strategies such as blockchain12.
• Scientific Publishing: She serves as Editor-in-Chief of the open-access journal PharmaceuticalIntelligence.com, which has published thousands of scientific articles and curated content in medicine and life sciences. The journal and its associated BioMed e-Series have reached in 2020 over 1.7 million readers and are widely used by professionals globally14.

As of April 27, 2025, the Journal PharmaceuticalIntelligence.com has garnered

• over 2,368,774 views and
• 1,506,446 visitors

• BioMed e-Series: Dr. Lev-Ari led the creation and editing of multi-volume e-book series in five medical specialties: cardiovascular diseases, genomics, cancer and oncology, immunology, and precision medicine. These e-books are available on Amazon and have been translated into Spanish to expand their reach124. See

https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/

• Conference Coverage: She has served as an invited press/media professional at more than 70 global conferences, producing real-time e-proceedings and tweet collections that are cited in journal articles and books24. See

https://pharmaceuticalintelligence.com/press-coverage/

• Research and Clinical Experience: Her expertise includes cardiovascular pharmacology and therapy research, drug discovery, and long-term acute care nursing management, with roles at institutions such as Northeastern University and various hospitals in Massachusetts145. See, all clinical positions:

Scientific and Medical Affairs Chronological CV

Academic and Industry Experience

• Education: Dr. Lev-Ari began her academic journey at Hebrew University, later earning a PhD from the University of California, Berkeley. She also completed studies in biological sciences, nursing, and pharmacology at Northeastern University5.
• Industry Roles: She has worked with start-ups and Fortune 100 companies as a management consultant and executive, contributing to algorithm-based decision support systems and electronic commerce analytics45.

Recognitions and Innovations

• Medical Education: Nominated for the 2018 Yidan Prize for her work in developing scientific content curation methodologies4.
• Intellectual Property: Creator of three intellectual property asset classes in scientific publishing and knowledge curation4.
• Methodology Development: Innovator in electronic Table of Contents (eTOCs) creation and real-time press coverage using social media for scientific conferences4.
• Elected advisor to the Governing Board of the Massachusetts Academy of Sciences and has been recognized for her contributions to scientific communication and education.2

• On 8/17/2018, Dr. Lev-Ari, PhD, RN was contacted by the President elect of the Massachusetts Academy of Sciences (MAS), Prof. Katya Ravid of Boston University, School of Medicine, to join MAS in the role of Liaison to the Biotechnology and eScientific Publishing industries for the term of August 2018-July 2021. In the MAS, Dr. Lev-Ari serve as Board member, Fellow, and Advisor to the Governing Board.

http://www.maacadsci.org

MAS FELLOWS 

GOVERNING BOARD

ACTIVITIES

Recognitions ADDED by Aviva Lev-Ari, PhD, RN

• 2019 Ranking of Conference Influencers: On 4/9/2019, The Partners’ 2019 World Medical Innovation Forum #WMIF19 via @symplur‘s #Healthcare Hashtags http://bit.ly/WMIF19 
  • By “Mentions” – Ranked #4: @pharma_BI and 
  • By “Tweets” – Ranked #2: @AVIVA1950

  via NodeXL  http://bit.ly/2KB6cPN 

  • By “Betweenness Centrality” – Ranked #3: @AVIVA1950 and @pharma_BI

https://pharmaceuticalintelligence.com/2019/04/13/the-wmif19-influencers-via-symplurs-healthcare-hashtags-http-bit-ly-wmif19-by-mentions-and-by-tweets-ranked-4-pharma_bi-and-2-aviva1950-respectively-ranked-3-via-node/

• December 6, 2019 – became Nominee for 2020 Campanile Excellence in Achievement Award. This award recognizes an alumnus/a whose remarkable professional lifetime achievements reflect the excellence of a UC Berkeley education. Nominator: Prof. Sheila M. Puffer (UC, Berkeley, PhD’84).

Past Recipients

https://awards.berkeley.edu/achievement-awards

The recipients will be had been formally presented with their awards at Berkeley Charter Gala on May 14, 2020.

• On 12/7/2018, Dr. Lev-Ari was nominated for 2019 Berkeley Alumna of the Year Achievement Award

2019 Awardees

https://awards.berkeley.edu/achievement-awards

From: Danielle Wiskerson <dwiskerson@berkeley.edu>

Subject: 2019 Achievement Awards update

Date: February 7, 2019 at 9:27:30 PM EST

To: spuffer@comcast.net

Dear Sheila:

On behalf of the Cal Alumni Association and the UC Berkeley Foundation Board of Trustees, we would like to thank you for your nomination of Aviva Lev-Ari for the Alumnus/a of the Year Award. Due to the high volume of qualified nominees, this year’s award process was difficult and Dr. Lev-Ari was not selected to be honored at this time.

We sincerely appreciate the effort you put into Dr. Lev-Ari’s nomination and thank you for participating in our award process. With support like yours, we will continue to acknowledge and award outstanding Berkeley alumni.

Sincerely,

Danielle

Danielle Wiskerson, Associate Director | External Relations

University of California, Berkeley | University Development and Alumni Relations

Achievements in Three Academic Disciplines

1. Pioneering implementations of Analytics to Business decision making

Pioneering implementations of analytics to business decision making: contributions to domain knowledge conceptualization, research design, methodology development, data modeling and statistical data analysis: Aviva Lev-Ari, UCB, PhD’83; HUJI MA’76

https://pharmaceuticalintelligence.com/2018/05/28/pioneering-implementations-of-analytics-to-business-decision-making-contributions-to-domain-knowledge-conceptualization-research-design-methodology-development-data-modeling-and-statistical-data-a/

2. Key Opinion Leader (KOL) in Pharmaceutical Business Intelligence

Digital KOL Parameters

Key Opinion Leader (KOL) – Aviva Lev-Ari, PhD, RN, as evidenced by

https://pharmaceuticalintelligence.com/2016/07/21/key-opinion-leader-kol-aviva-lev-ari-phd-rn-as-evidenced-by/

3. Medical Education Development: Content Creation in five Specialties in Medicine and Life Sciences

The Voice of Prof. Marc Feldman

https://profiles.stanford.edu/marcus-feldman

“Dr. Lev-Ari founded the LPBI Group (Leaders in Pharmaceutical Business Intelligence Group) in 2012 as a start-up dedicated to electronic publishing in the biomedical sciences. She continues as editor-in-chief of LPBI’s open access scientific journals. After a twenty-year career as an executive in research and technology, she re-invented herself and devoted her life to health care. She studied biological science at Northeastern University, then nursing and became a registered nurse in 2008. She was involved in cardiovascular research through pharmacological therapy while studying at Northeastern, during which she developed her skills at recognizing valuable and innovative research. She worked in long-term post-acute episode nursing management, which enabled her to see health care from the patient’s perspective. The clinical perspective dominates the Journal’s articles.

https://pharmaceuticalintelligence.com/about/

 

• Reflections on a Four-phase Career: Aviva Lev-Ari, PhD, RN, March 2018

Was prepared for publication in American Friends of the Hebrew University (AFHU), May 2018 Newsletter, Hebrew University’s HUJI Alumni Spotlight Section.

Aviva Lev-Ari’s profile was up on 5/3/2018 on AFHU website under the Alumni Spotlight at https://www.afhu.org/

• On 5/11/2018, Excerpts were Published in AFHU e-news.

https://us10.campaign-archive.com/?u=5c25136c60d4dfc4d3bb36eee&id=757c5c3aae&e=d09d2b8d72

https://www.afhu.org/2018/05/03/aviva-lev-ari/

Sources ADDED by Aviva Lev-Ari, PhD, RN

• The Digital Age Gave Rise to New Definitions – New Benchmarks were born on the World Wide Web for the Intangible Asset of Firm’s Reputation: Pay a Premium for buying e-Reputation
• Professional Self Re-Invention: From Academia to Industry – Opportunities for PhDs in the Business Sector of the Economy
• Data Science & Analytics: What do Data Scientists Do in 2020 and a Pioneer Practitioner’s Portfolio of Algorithm-based Decision Support Systems for Operations Management in Several Industrial Verticals
• Thriving at the Survival Calls during Careers in the Digital Age – An AGE like no Other, also known as, DIGITAL

Dr. Lev-Ari’s career, as presented in Reflections on a Four-phase Career: Aviva Lev-Ari, PhD, RN, March 2018, has the following phases:

• Phase 1: Research, 1973 – 1983
• Phase 2: Corporate Applied Research in the US, 1985 – 2005
• Phase 3: Career Reinvention in Health Care, 2005 – 2012
• Phase 4: Electronic Scientific Publishing, 4/2012 to present

https://pharmaceuticalintelligence.com/2018/03/06/reflections-on-a-four-phase-career-aviva-lev-ari-phd-rn-march-2018/

Recollections of Years at UC, Berkeley, Part 1 and Part 2

• Recollections: Part 1 – My days at Berkeley, 9/1978 – 12/1983 – About my doctoral advisor, Allan Pred, other professors and other peers

https://pharmaceuticalintelligence.com/2018/03/15/recollections-my-days-at-berkeley-9-1978-12-1983-about-my-doctoral-advisor-allan-pred-other-professors-and-other-peer/

• Recollections: Part 2 – “While Rolling” is preceded by “While Enrolling” Autobiographical Alumna Recollections of Berkeley – Aviva Lev-Ari, PhD’83

https://pharmaceuticalintelligence.com/2018/05/24/recollections-part-2-while-rolling-is-preceded-by-while-enrolling-autobiographical-alumna-recollections-of-berkeley-aviva-lev-ari-phd83/

 

Selected Resources – Perplexity.ai, Version 2 (continued)

• LinkedIn Profile: [Aviva Lev-Ari, PhD, RN – LinkedIn]1
• LPBI Group Website: [pharmaceuticalintelligence.com]1
• BioMed e-Series (e-Books): [BioMed e-Series]4
• Amazon Author Page: [Aviva Lev-Ari on Amazon]4
• Contributor Biography: [Aviva Lev-Ari, PhD, RN – Contributor Biography]4
• Press Releases and Conference Coverage: [Press Releases]2, [Conference Coverage]4

Areas of Expertise

• Electronic scientific publishing and curation
• Cardiovascular disease research and pharmacotherapy
• Drug discovery and delivery
• Medical text analysis (NLP, ML, AI)
• Healthcare management and nursing
• Scientific communication and education

Dr. Aviva Lev-Ari’s work has significantly advanced the accessibility and organization of biomedical research, supporting both professional education and public understanding in the life sciences1245.

Related topics identified by Perplexity.ai and researched by Gemini 2.5 Pro (experimental)

The following three related questions generated by Perplexity are here answered by Gemini 2.5 Pro (experimental)

A. What are some notable collaborations Aviva Lev-Ari has been involved in

B. How does Aviva Lev-Ari’s role as Editor-in-Chief influence the content of the pharmaceuticalintelligence.com journal

C. What are the future plans for LPBI Group under Aviva Lev-Ari’s leadership

 

A. Names of Aviva Lev-Ari, PhD, RN Collaborators in Books

By Gemini 2.5 (experimental)

https://gemini.google.com/app/1b81dd71f52faf40?prompt_id=3e72b4a6f9&prompt_action=autosubmit&utm_source=sem&utm_source=google&utm_medium=paid-media&utm_medium=cpc&utm_campaign=hardcode_student_offer_autosubmit&utm_campaign=2024enUS_gemfeb&gad_source=5&gad_campaignid=22469371566&gclid=EAIaIQobChMIzMne2NT9jAMVZTUIBR0z9zZiEAAYASAAEgJAEvD_BwE&gclsrc=aw.ds

Show thinking

Based on the search results, Aviva Lev-Ari, PhD, RN has collaborated with numerous individuals on various e-books, primarily within the context of the Leaders in Pharmaceutical Business Intelligence (LPBI) Group’s BioMed e-Series, often available on Amazon Kindle. She served variously as an author, editor, or the overall Editor-in-Chief for these series.

Here are names of collaborators identified from specific book projects:

1. On “The VOICES of Patients, Hospitals CEOs, Health Care Providers, Caregivers and Families: Personal Experience with Critical Care and Invasive Medical Procedures…”:  
   • Larry H. Bernstein (Author/Editor)
   • Stephen J. Williams (Author)
   • Ferez Nallaseth (Author)
   • Itzhak Brook (Author)
   • Sudipta Saha (Author)
   • Demet Sag (Author)
   • Ritu Saxena (Author)
   • Tilda Barliya (Author)
   • Gail S. Thornton (Author/Co-editor)

• Aviva is a curator of several articles and the designer of the e-Book’s electronic Table of Contents
• Aviva wrote the Book introduction
• Aviva is not the Editor of this e-Book [the only case for the BioMed e-Series]

1. On “Contributions to Biological Sciences by Scientific Leaders in the 21st Century…”:

• Larry H. Bernstein (Author)
• Stephen J. Williams (Author)

3. On “Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS & BioInformatics, Simulations and the Genome Ontology”:

• Stephen Williams (Author/Editor)
• Marcus W. Feldman (Author/Editor)
• Larry H. Bernstein (Author)
• Sudipta Saha (Author)
• Dror Nir (Author)
• Irina Robu (Author)
• Gail S. Thornton (Author)

(Note: There’s conflicting information in sources whether Aviva Lev-Ari was an author or editor on this specific title, but these individuals collaborated on the work).

• Aviva is e-Book Editor and curator, designer of eTOC

4. On “Human Reproductive System, Genomic Endocrinology and Cancer Types”:

• Stephen J. Williams (Author/Editor)
• Sudipta Saha (Author/Editor)
• Larry H. Bernstein (Author)
• Prabodah Kandala (Author)
• Irina Robu (Author)
• Marcus W. Feldman (Author) (Note: Aviva Lev-Ari is listed as both author and editor here).

Aviva is e-Book Editor and curator, designer of eTOC

5. On “Pharmacological Agents in Treatment of Cardiovascular Diseases”:
   • Justine D. Pearlman (Author/Editor)
   • Larry H. Bernstein (Author/Editor)
   • Sudipta Saha (Author)
   • Demet Sag (Author)
   • Dan Dragoi (Author)
   • Vinod Vivek Lal (Author)

Aviva is e-Book Editor and curator, designer of eTOC

5. On “Genomics Orientations for Personalized Medicine”:
   • Larry H. Bernstein (Editor)
   • Stephen J. Williams (Editor)

Aviva is a curator and one of three e-Book Editors

5. On “Results of Medical Text Analysis with Natural Language Processing (NLP)…”:
   • Madison Davis (Author)
   • Stephen J. Williams (Editor)
   • Marcus W. Feldman (Editor)

Aviva is e-Book Editor and curator, designer of eTOC

Additionally, names like Adam Sonnenberg, Feng Liu, and Shyh-Dar Li appear as co-authors in publication databases like ResearchGate linked to Aviva Lev-Ari, but the specific format (book vs. article) isn’t always clear from those summaries alone. Her role as Editor-in-Chief also implies collaboration with all contributing authors within the extensive LPBI e-book series.

crossing text added by Aviva Lev-Ari.

B. How does Aviva Lev-Ari’s role as Editor-in-Chief influence the content of the pharmaceuticalintelligence.com journal

By Gemini 2.5 Pro (experimental)

https://gemini.google.com/app/1b81dd71f52faf40?prompt_id=3e72b4a6f9&prompt_action=autosubmit&utm_source=sem&utm_source=google&utm_medium=paid-media&utm_medium=cpc&utm_campaign=hardcode_student_offer_autosubmit&utm_campaign=2024enUS_gemfeb&gad_source=5&gad_campaignid=22469371566&gclid=EAIaIQobChMIzMne2NT9jAMVZTUIBR0z9zZiEAAYASAAEgJAEvD_BwE&gclsrc=aw.ds

Show thinking

Okay, let’s break down how Aviva Lev-Ari’s role as Editor-in-Chief (and her related roles) influences the content of pharmaceuticalintelligence.com.

It’s important to note that Dr. Lev-Ari is not only the Editor-in-Chief but also the Founder, Administrator, Architect, and IP owner of the Leaders in Pharmaceutical Business Intelligence (LPBI) Group and its platform, pharmaceuticalintelligence.com. This combination of roles gives her profound and multifaceted influence over the journal’s content.

Here’s how her influence manifests:

1. Setting the Vision and Strategic Direction: As the founder and leader, she defines the overall mission, scope, and strategic focus of the journal. This includes deciding which areas within pharmaceuticals, life sciences, medicine, and MedTech will be prioritized. Initiatives like the BioMed e-Series, conference coverage, and the focus on Medical Text Analysis using NLP reflect her strategic vision.
2. Developing the Core Content Methodology: Lev-Ari developed the “curation” methodology central to the journal. This involves synthesizing, analyzing, and interpreting complex research findings (often from peer-reviewed articles) to make them accessible and understandable to a broader audience, including practicing professionals and students. This methodology fundamentally shapes the style and purpose of the content.
3. Direct Content Creation and Curation: She is a prolific contributor herself, having authored or curated a very large percentage of the articles published on the platform (one source mentioned over 58%). Her direct involvement ensures the content aligns with her standards and vision.
4. Topic Selection and Ontology Development: As EIC and architect, she guides the selection of topics covered. She was involved in developing the extensive research category ontology (over 740 categories mentioned), which structures the journal’s content and influences how information is organized and discovered.
5. Assembling and Leading the Team: She personally recruited and leads the team of Experts, Authors, and Writers (EAWs) who contribute content. Her leadership guides their work and ensures contributions align with the journal’s focus.
6. Overseeing Editorial Processes: In her EIC capacity, she is ultimately responsible for the editorial standards and the final decisions on what gets published, ensuring quality and relevance.
7. Initiating Special Projects and Formats: She developed unique content formats like the electronic Table of Contents (eTOCs) for the e-Books (culled from journal articles) and the methodology for real-time conference coverage using social media (producing e-Proceedings and Tweet collections). These initiatives directly generate specific types of content for the platform.

In essence, Aviva Lev-Ari’s influence extends far beyond a traditional Editor-in-Chief (EIC) role. As the founder and architect with a clear vision and a hands-on approach to content creation and methodology development, she fundamentally shapes the scope, style, structure, and specific topics covered in pharmaceuticalintelligence.com.

 

C. What are the future plans for LPBI Group under Aviva Lev-Ari’s leadership

By Gemini 2.5 Pro (experimental)

https://gemini.google.com/app/1b81dd71f52faf40?prompt_id=3e72b4a6f9&prompt_action=autosubmit&utm_source=sem&utm_source=google&utm_medium=paid-media&utm_medium=cpc&utm_campaign=hardcode_student_offer_autosubmit&utm_campaign=2024enUS_gemfeb&gad_source=5&gad_campaignid=22469371566&gclid=EAIaIQobChMIzMne2NT9jAMVZTUIBR0z9zZiEAAYASAAEgJAEvD_BwE&gclsrc=aw.ds

Show thinking

Based on the available information, the future plans for LPBI Group under Aviva Lev-Ari’s leadership, often referred to as the “2.0 LPBI” vision (primarily outlined for the 2021-2025 timeframe), center on leveraging the group’s extensive intellectual property portfolio through advanced technologies and strategic initiatives.

Key future plans and strategic directions include:

1. Medical Text Analysis using AI/NLP/ML:
   • Utilizing the vast content repository (+6,200 articles, 48 e-books, conference proceedings, etc., totaling over 8-9 gigabytes) as training data for Natural Language Processing (NLP), Machine Learning (ML), and Artificial Intelligence (AI) algorithms.
   • The goal is to extract deeper insights, identify relationships (e.g., hypergraphs), create value-added knowledge products, and potentially offer new services (Software as a Service – SaaS). This includes experimenting with models like ChatGPT, BioGPT, Grok, and potentially fine-tuning foundation models.
2. Content Monetization via Blockchain:
   • Exploring the use of blockchain technology to manage IP securely and potentially monetize content through controlled access or narrowcasting to specific healthcare communities (Blockchain as a Service – BaaS). This could involve features like permissions, smart contracts, and immutable ledgers.
3. Expanding Content Formats and Reach:
   • Audio Conversion: Converting existing text content (articles, e-books) into audio formats like podcasts and audio files (e.g., on SoundCloud), enhancing accessibility and reach.
   • Translations: Continuing and potentially expanding the translation of content (e.g., e-books) into other languages beyond Spanish (Japanese and Russian were previously mentioned as possibilities).
4. Developing Podcasts: Creating audio podcasts, likely focusing on interviews or discussions with scientific leaders, primarily as a means to build reputation and engagement within the pharmaceutical and biomedical communities.
5. Strategic Partnerships and Potential Exit: Actively exploring options to transition from a sole owner-operator model. This includes seeking joint ventures, partnerships, or potentially an M&A transaction involving the transfer of the IP portfolio and team expertise.

The overarching strategy appears to be transforming LPBI Group from primarily an electronic scientific publisher into a company that generates value through data analysis (AI/NLP) and potentially secure content distribution (Blockchain), while exploring structural changes for future growth or transition.

Updated on 5/2/2025

Looking to the future, the future looks bright. Aviva and her team’s intellectual property, encompassing their vast repository of scientific articles, e-books, images, podcasts, and conference proceedings, will serve as crucial training data for building a Multimodal Healthcare Foundation Model. This innovative approach, as outlined on https://pharmaceuticalintelligence.com/healthcare-foundation-model/, will leverage her team’s expert knowledge to enhance healthcare AI technologies, promising to revolutionize the way healthcare is delivered and understood. By integrating their extensive content into AI training datasets, Aviva and her team are poised to lead the next wave of advancements in healthcare, ensuring that their legacy continues to drive progress and innovation.

https://pharmaceuticalintelligence.com/2025/04/30/interactive-chat-with-grok-created-by-xai-lpbi-groups-legacy-and-biography-of-aviva-lev-ari-phd-rn-founder-director/

Perplexity.ai answers to Related topics it generated by AI:

• What inspired Aviva Lev-Ari to start the Leaders in Pharmaceutical Business Intelligence Group

Aviva Lev-Ari was inspired to start the Leaders in Pharmaceutical Business Intelligence (LPBI) Group by a unique combination of her academic background, professional experiences, and a clear vision for advancing biomedical knowledge dissemination. Several key factors contributed to the founding of LPBI Group:

• Interdisciplinary Academic Training: Dr. Lev-Ari’s education spans planning (M.A. from Hebrew University), industrial organization economics (Ph.D. from UC Berkeley), and extensive coursework in biological sciences and nursing. This multidisciplinary foundation enabled her to conceptualize innovative models for organizing and sharing scientific information3.
• Experience in Research and Healthcare: Her hands-on work in pharmacotherapy research, where she developed new combination drug therapies, and her clinical management roles in healthcare facilities, highlighted gaps in how cutting-edge biomedical knowledge was curated and shared among professionals35.
• Pioneering Curation Methodology: Recognizing the need for a new approach to scientific publishing, Dr. Lev-Ari developed a methodology for curating and organizing biomedical content. She aimed to transition from traditional academic publishing to an open-access, online journal style, making research more accessible and interactive for a global audience3.
• Desire for Global Collaboration and Impact: Dr. Lev-Ari envisioned LPBI as a platform for international collaboration, leveraging expert contributions and digital tools to create a dynamic knowledge exchange in medicine, pharma, and life sciences. She also saw the potential for social media and digital publishing to amplify the reach and impact of curated scientific content31.
• Personal Drive for Innovation: Her career reflects a recurring theme of innovation-whether in analytics for business decision-making, the creation of new publication ontologies, or the architecture of e-books and electronic tables of contents. The launch of LPBI Group was a natural progression of her drive to create value at the intersection of science, technology, and publishing32.

In summary, Aviva Lev-Ari founded LPBI Group to address the need for advanced, accessible, and collaborative scientific publishing, drawing on her extensive interdisciplinary expertise and a passion for transforming how biomedical knowledge is curated and disseminated worldwide312.

 

• How has Aviva Lev-Ari’s work impacted the field of cardiovascular diseases – her major field of interest

Aviva Lev-Ari’s work has made a substantial impact on the field of cardiovascular diseases through a combination of original research, innovative content curation, and the development of educational resources.

Key Contributions

• Original Research and Drug Development: Lev-Ari developed a combination drug therapy aimed at preventing major cardiovascular events during her tenure at Northeastern University (2006–2007). This research was among the first articles published on PharmaceuticalIntelligence.com, highlighting her direct contributions to therapeutic innovation in cardiovascular care23.
• Curated Knowledge and Educational Resources: She authored and curated six e-books specifically focused on cardiovascular diseases, covering topics such as nitric oxide mechanisms, epigenetics and genomics, regenerative medicine, pharmacotherapies, and interventional cardiology. These resources provide comprehensive, up-to-date information for clinicians, researchers, and students, and have become valuable educational tools in the field13.
• Methodology for Clinical Interpretation: Lev-Ari pioneered a methodology for curating and clinically interpreting research findings from basic science articles, which she applied in the open-access journal PharmaceuticalIntelligence.com. This approach has helped bridge the gap between research and clinical practice, making complex findings more accessible and actionable for healthcare professionals2.
• Focus on Genetics, Biomarkers, and Preventive Medicine: Her work includes extensive coverage of the genetic and epigenetic bases of cardiovascular diseases, the identification and clinical relevance of biomarkers (such as microRNAs and lipid profiles), and the integration of genomics into preventive cardiology and personalized medicine4.
• Advocacy for Preventive Strategies: Lev-Ari has emphasized the importance of physical activity, lifestyle modification, and evidence-based preventive medicine in reducing cardiovascular risk, providing curated content on these topics to guide both practitioners and the public4.

Impact Summary

Through her research, editorial leadership, and innovative curation, Aviva Lev-Ari has significantly advanced the dissemination of knowledge in cardiovascular medicine. Her work has enabled faster translation of research into clinical practice, fostered interdisciplinary education, and promoted the adoption of personalized and preventive strategies in cardiovascular disease management1234.

To See all LPBI Group’s e-Books on Amazon.com

https://www.amazon.com/s?k=Aviva+Lev-Ari&i=digital-text&rh=n%3A133140011&ref=nb_sb_noss

https://pharmaceuticalintelligence.com/press-releases/

https://pharmaceuticalintelligence.com/five-bilingual-biomed-e-series/

https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/

 

Aviva Lev-Ari’s six e-Books on cardiovascular diseases cover the following main themes:

ADDED by Aviva Lev-Ari:

See all the six volumes LINKS on Amazon.com

 

Series A: Cardiovascular Diseases ($515)

https://www.amazon.com/gp/product/B07P981RCS?ref_=dbs_p_mng_rwt_ser_shvlr&storeType=ebooks

 

Spanish-language Edition and English-language Edition

 

Spanish-language Edition

EDICIÓN EN ESPAÑOL

Serie A: Spanish Audio Edition is found on Amazon.com ($385)

Serie A: Libros electrónicos acerca de las enfermedades cardiovasculares

(6 books) Kindle Edition

https://www.amazon.com/gp/product/B0BPR9L1ZX?ref_=dbs_p_pwh_rwt_anx_a_lnk

Volume Titles & URL on Amazon.com

 

• Serie A, Volumen 1:

Puntos de vista acerca del óxido nítrico en los mecanismos patogénicos 

(Spanish Edition) Kindle Edition. 2022

https://www.amazon.com/dp/B0BPST4B4N $56

 

• Serie A, Volumen 2:

Investigación original cardiovascular: casos de diseño de metodología para la selección de contenidos El arte de la selección de contenidos científicos y médicos

(Spanish Edition) Kindle Edition. 2022

https://www.amazon.com/dp/B0BPRBVLD3 $56

 

• Serie A, Volumen 3:

Etiología de las enfermedades cardiovasculares: epigenética, genética y genómica

(Spanish Edition) Kindle Edition. 2022

https://www.amazon.com/dp/B0BPR8ZCT3 $56

 

• Serie A, Volumen 4:

Medicina regenerativa y Medicina traslativa La promesa terapéutica para las enfermedades cardiovasculares

(Spanish Edition) Kindle Edition. 2022

https://www.amazon.com/dp/B0BPRC2WQY $56

 

• Serie A, Volumen 5:

Agentes farmacológicos en el tratamiento de las enfermedades cardiovasculares

(Spanish Edition) Kindle Edition. 2022

https://www.amazon.com/dp/B0BPRCZ1QF $86

 

• Serie A, Volumen 6:

Cardiología intervencionista para el diagnóstico de enfermedades y cirugía cardíaca para el tratamiento de afecciones

(Spanish Edition) Kindle Edition. 2022

https://www.amazon.com/dp/B0BPRDLFNH $75

 

ENGLISH-language EDITION

Series A: English-language Text Edition is found on Amazon.com ($515) 

Series A: Cardiovascular Diseases

(6 book series) Kindle Edition

https://www.amazon.com/dp/B07MVF34ZC/ref=sr_1_1?s=digital-text

 

• Series A, Volume One

 Perspectives on Nitric Oxide in Disease Mechanisms, 2013

(English Edition) Kindle Edition

http://www.amazon.com/dp/B00DINFFYC $75

 

• Series A, Volume Two 

Cardiovascular Original Research: Cases in Methodology Design for Content Co-Curation, 2015

(English Edition) Kindle Edition

 http://www.amazon.com/dp/B018Q5MCN8 $75

 

• Series A, Volume Three

Etiologies of Cardiovascular Diseases – Epigenetics, Genetics and Genomics, 2015

(English Edition) Kindle Edition

http://www.amazon.com/dp/B018PNHJ84 $75

 

• Series A, Volume Four

 Therapeutic Promise: Cardiovascular Diseases, Regenerative & Translational Medicine, 2015

(English Edition) Kindle Edition

http://www.amazon.com/dp/B019UM909A $75

 

• Series A, Volume Five

Pharmacological Agents in Treatment of Cardiovascular Diseases, 2018

(English Edition) Kindle Edition

https://www.amazon.com/dp/B07MGSFDWR  $115

 

• Series A, Volume Six:

 Interventional Cardiology for Disease Diagnosis and Cardiac Surgery for Condition Treatment, 2018

(English Edition) Kindle Edition

https://www.amazon.com/dp/B07MKHDBHF $100

 

 Perplexity.ai Version 2, continues:

1. Perspectives on Nitric Oxide in Disease Mechanisms
   This volume explores the role of nitric oxide in cardiovascular disease pathophysiology and mechanisms15.
2. Cardiovascular Original Research: Cases in Methodology Design for Content Co-Curation
   Focuses on original research studies and the methodology for curating and interpreting cardiovascular research findings15.
3. Etiologies of Cardiovascular Diseases – Epigenetics, Genetics & Genomics
   Covers genetic and epigenetic factors, genomics, biomarkers, and the influence of these on cardiovascular disease development and individualized medicine135.
4. Therapeutic Promise: Cardiovascular Diseases, Regenerative & Translational Medicine
   Reviews advances in regenerative medicine and translational therapies aimed at cardiovascular disease treatment25.
5. Pharmaco-Therapies for Cardiovascular Diseases
   Discusses pharmacological treatments and drug therapies for cardiovascular conditions, including their mechanisms and clinical applications25.
6. Interventional Cardiology, Cardiac Surgery, and Cardiovascular Imaging for Disease Diagnosis and Guidance of Treatment
   Provides a comprehensive review of interventional cardiology techniques, cardiac surgery, and imaging modalities used for diagnosis and treatment guidance25.

These volumes collectively address causes, risks, biomarkers, therapeutic implications, and advanced diagnostic and treatment strategies in cardiovascular medicine, offering a broad and in-depth resource for clinicians, researchers, and students235.

 

Perplexity.ai is asking:

What are the most significant biomarkers identified in Aviva Lev-Ari’s e-Books on cardiovascular diseases

Perplexity.ai answers:

The most significant biomarkers identified in Aviva Lev-Ari’s e-Books on cardiovascular diseases include:

• MicroRNAs (miRNAs):

• • miR-1, miR-133a, miR-208b, and miR-499 are highlighted as serum biomarkers indicating myocardial damage in conditions such as acute myocardial infarction, viral myocarditis, diastolic dysfunction, and acute heart failure1.

• C-Reactive Protein (CRP) and High Sensitivity CRP (hs-CRP):

• • Widely discussed as key inflammatory biomarkers for cardiovascular risk assessment, coronary heart disease, and ischemic stroke13.

• Plasma Fibrinogen:

• • An established marker for cardiovascular risk and vascular disease, reflecting inflammation and coagulation status138.

• Serum Pentraxin 3:

• • A newly identified inflammatory marker that indicates the complexity and severity of coronary artery disease, especially in patients with stable angina3.

• Lipid Profile Markers:

• • LDL cholesterol, small dense LDL particles, HDL cholesterol, and apolipoprotein A1 (apoA1) are used for risk assessment and monitoring of atherosclerosis and coronary artery disease135.

• Genetic Risk Loci:

• • Identification of 15 novel genetic loci associated with coronary artery disease, reflecting the role of genomics in personalized risk prediction13.

• Natriuretic Peptides:

• • Biomarkers such as BNP (B-type natriuretic peptide) and NT-proBNP are important for diagnosing and managing heart failure1.

• Galectin-3:

• • Recognized for its role in cardiac fibrosis, remodeling, and as a marker in heart failure management14.

• Endothelin System Markers:

• • Used to assess the pathophysiological role in chronic heart failure and acute coronary syndromes1.

• Coronary Calcium Score (by CT scan):

• • An imaging biomarker used to assess atherosclerotic burden and guide statin therapy decisions1.

• Markers Related to the Actin Cytoskeleton:

• • Emerging biomarkers relevant to cardiac structure and function13.

These biomarkers span molecular, genetic, proteomic, and imaging domains, enabling comprehensive risk assessment, diagnosis, and management of cardiovascular diseases as detailed in Aviva Lev-Ari’s curated e-Books134.

 

What are the key biomarkers discussed in Aviva Lev-Ari’s e-Books

Answer

Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Aviva Lev-Ari, PhD, RN, Director and Founder

 

PubMed

Amyloid-β and Phosphorylated Tau are the Key Biomarkers and …

 

Leaders in Pharmaceutical Business Intelligence Group, LLC, Doing Business As LPBI Group, Newton, MA

The Methodology of Curation for Scientific Research Findings

+5 sources

The key biomarkers discussed in Aviva Lev-Ari’s e-Books on cardiovascular diseases span genetic, molecular, proteomic, and clinical domains, reflecting the complexity of cardiovascular diagnostics and risk assessment. Major biomarker categories and specific examples include:

• Genetic and Genomic Biomarkers:

• • Variants identified through genomics and genetic studies, such as those influencing susceptibility to hypertension, statin response, and risk of myocardial infarction.
  • Genomic markers from large studies like the Framingham Heart Study and Jackson Heart Study, which inform individualized and preventive cardiology3.

• Proteomic and Molecular Biomarkers:

• • Markers involved in endothelium function, angiogenesis, and disordered coagulation.
  • Inflammatory markers, atherosclerotic markers, and those associated with heart failure.
  • Myocardial injury markers, such as cardiac troponins, which are critical for diagnosing acute coronary syndromes3.

• Metabolic and Clinical Biomarkers:

• • Serum calcium levels, particularly upper-normal range calcium as a risk biomarker for diabetes and its cardiovascular implications.
  • Lipid profiles, including hyperlipidemia and hypercholesterolemia, as risk factors and biomarkers for cardiovascular diseases3.

• Novel and Emerging Biomarkers:

• • MicroRNAs (miRNAs) and other non-coding RNAs, which have roles in gene regulation and are increasingly recognized as diagnostic and prognostic markers.
  • Biomarkers related to nitric oxide signaling pathways, reflecting the importance of endothelial function in cardiovascular health3.

• Other Notable Biomarkers:

• • Platelet function markers and platelet-endothelial interactions, relevant for atherosclerosis and thrombosis.
  • Calcium signaling molecules, including calmodulin kinases and ryanodine receptors, particularly in the context of arrhythmias and atrial fibrillation3.

These biomarkers are discussed in the context of their diagnostic, prognostic, and therapeutic implications, supporting the move toward personalized and preventive cardiovascular medicine3.

 

Sources identified and used by Perplexity.ai

https://www.perplexity.ai/search/i-wish-to-get-a-description-an-KfyRhnOWSmWDJ3DNGY0MoA?0=r

1

linkedin

linkedin.com/in/avivalevari

Aviva Lev-Ari, PhD, RN – Leaders in Pharmaceutical … – LinkedIn

Dr. Aviva Lev-Ari, Ph.D., RN, is an important innovator in the domain of electronic scientific publishing.

2

Leaders in Pharmaceutical Business Intelligence (LPBI) Group

pharmaceuticalintelligence.com/contributors-b…

Aviva Lev-Ari, PhD, RN, Director and Founder

Aviva Lev-Ari, PhD, RN (o) 1-617-244-4024 (m) 1-617-775-0451 avivalev-ari@alum.berkeley.edu Director & Founder Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston Editor…

3

Leaders in Pharmaceutical Business Intelligence (LPBI) Group

pharmaceuticalintelligence.com/knowledge-port…

Aviva Lev-Ari, PhD, RN, Founder, LPBI Group: 1.0 & 2.0

Aviva Lev-Ari, PhD, RN Director & Founder Leaders in Pharmaceutical Business Intelligence (LPBI) Group UPDATED on 12/26/2023 On 12/24/2023 Published: Contributions to Biological Sciences by Sci…

 

4

Leaders in Pharmaceutical Business Intelligence Group, LLC, Doing Business As LPBI Group, Newton, MA

pharmaceuticalintelligence.com/press-releases

Press Releases | Leaders in Pharmaceutical Business Intelligence …

LBPI Group chooses Montero Language Services for important medical translations 25, May 2023 Montero Life Science “A miracle that came true”. This is how Aviva Lev-Ari, PhD, RN founder of LPBI Grou…

 

5

American Friends of the Hebrew University

afhu.org/2018/05/03/avi…

Aviva Lev-Ari – American Friends of the Hebrew University

Aviva Lev-Ari (nee Abraham) began her studies at Hebrew University in 1970 in geography and history, and later received her master’s degree in the Urban

 

6

Linkedin

linkedin.com/posts/avivalev…

Aviva Lev-Ari, PhD, RN – Founder’s Bio – LinkedIn

Founder’s Bio

 

7

Linkedin

linkedin.com/posts/avivalev…

Aviva Lev-Ari, PhD, RN – LinkedIn

I recommmend Montero LS for translation of medical content. We used English to Spanish pharmaceutical, life sciences, medical and healthcare content. 25, May…

 

8

scribd

scribd.com/doc/85050250/D…

Director Pharmaceutical Business Intelligence in Boston MA … – Scribd

Aviva Lev-Ari is a seasoned technology executive with proven expertise running collaborative teams in R&D and Operations in the areas of electronic commerce …

9

x

x.com/AVIVA1950/status…

Aviva Lev-Ari on X: “https://t.co/nSm3EsbClN LBPI Group chooses …

… Aviva Lev-Ari, PhD, RN founder of LPBI Group described what she and her venture had accomplished by partnering with Montero for a “monumental” #Medicine …

10

Leaders in Pharmaceutical Business Intelligence Group, LLC, Doing Business As LPBI Group, Newton, MA

pharmaceuticalintelligence.com/biomed-e-books…

https://pharmaceuticalintelligence.com/biomed-e-books/

Volume Three: Cancer Patients’ Resources on Therapies | Leaders …

Series C: e-Books on Cancer & Oncology Series C Content Consultant: Larry H. Bernstein, MD, FCAP VOLUME THREE Cancer Patients’ Resources on Therapies 2020 Editor: Stephen J. Williams, PhD…

 

11

goodreads

goodreads.com/author/show/89…

Aviva Lev-Ari (Author of Cancer Biology and Genomics for Disease …

Aviva Lev-Ari’s Books · Cancer Biology and Genomics for Disease Diagnosis by Larry H Bernstein MD FCAP · Etiologies of Cardiovascular Diseases by Justin D.

12

linkedin

linkedin.com/posts/avivalev…

Press Releases | Aviva Lev-Ari, PhD, RN – LinkedIn

Plain language summaries of publications of company-sponsored medical research: what key questions do we need to address?

13

muckrack

muckrack.com/aviva-lev-ari-…

Articles by Aviva Lev-Ari’s Profile | MedTech Intelligence Journalist …

Articles by Aviva Lev-Ari on Muck Rack. Find Aviva Lev-Ari’s email address, contact information, LinkedIn, Twitter, other social media and more.

14

linkedin

linkedin.com/posts/avivalev…

Aviva Lev-Ari, PhD, RN’s Post – LinkedIn

Aviva Lev-Ari, PhD, RN’s Post · Press Release for Five Bilingual BioMed e-Series · More from this author · Explore topics.

15

rocketreach

rocketreach.co/aviva-lev-ari-…

Aviva Lev-Ari Email & Phone Number | Leaders in Pharmaceutical …

Aviva Lev-Ari, based in Newton, MA, US, is currently a Founder 2.0 LPBI at Leaders in Pharmaceutical Business Intelligence Group. Aviva Lev-Ari brings …

16

open.spotify

open.spotify.com/show/3dj9DL1t0…

Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Leaders in Pharmaceutical Business Intelligence (LPBI) Group. Aviva Lev-Ari. Follow. Funding, Deals & Partnerships: BIOLOGICS & MEDICAL DEVICES; BioMed e …

17

linkedin

linkedin.com/today/author/a…

Aviva Lev-Ari, PhD, RN – LinkedIn

Aviva Lev-Ari, PhD, RN. Founder 1.0 LPBI and 2.0 LPBI at Leaders in Pharmaceutical Business Intelligence Group, LLC. View articles by Aviva Lev-Ari, …

18

muckrack

muckrack.com/aviva-lev-ari-…

Aviva Lev-Ari’s Profile | MedTech Intelligence Journalist – Muck Rack

Find Aviva Lev-Ari of MedTech Intelligence’s articles, email address, contact information, Twitter and more.

19

success.ai

success.ai/profile/aviva-…

Aviva LevAri Email & Phone Number | Founder 1.0 LPBI and 2.0 …

To contact Aviva LevAri send an email to aviva.levari@pharmaceuticalintelligence.com

 

20

twitter

twitter.com/aviva1950

Aviva Lev-Ari (@AVIVA1950) / X

This is how Aviva Lev-Ari, PhD, RN founder of LPBI Group described what she and her venture had accomplished. Show more. LBPI Group chooses Montero Language …

21

x

x.com/AVIVA1950/status…

1. Aviva Lev-Ari on X: “#Healthcare #Foundation #Model https://t.co …
2. Healthcare Foundation Model Mission: Design of an Artificial Intelligence [AI-built] Healthcare Foundation Model driven by and derived from Medical Expert …
3. Leaders in Pharmaceutical Business Intelligence (LPBI) Group
4. pharmaceuticalintelligence.com/2018/03/06/ref…
5. Reflections on a Four-phase Career: Aviva Lev-Ari, PhD, RN, March 2018
6. Reflections on a Four-phase Career: Aviva Lev-Ari, PhD, RN, March 2018 Updated on 10/18/2022 Prepared for publication in American Friends of the Hebrew University (AFHU), May 2018 Newsletter…

 

APPENDIX ADDED by Aviva Lev-Ari on 5/2/2025

CV Format

https://www.linkedin.com/in/avivalevari/

Publication List

• Scientific and Medical Affairs Chronological CV
• Technology Executive, Methodology and Decision Scientist, Functional CV
• Contributions to Design of Algorithm-based Decision Support Systems
• Technical Contributions in the Domain of Electronic Commerce Analytics: Aviva Lev-Ari, Ph.D.
• HealthCare Delivery – Long Term Post Acute Care Nursing Management CV
• Editorials & Publications of Articles in e-Books by Leaders in Pharmaceutical Business Intelligence (LPBI) Group: Contributions by Aviva Lev-Ari, PhD, RN
• List of Invited Lectures, 1983 -2004
• List of Publications, 1983 – 2004
• List of Publications, 2006 – Present
• Cardiovascular Diseases and Pharmacological Therapy: Curations, 2006 – 4/2018
• MedTech & Medical Devices for Cardiovascular Repair – Curations
• Stem Cells and Cardiac Repair: Content Curation & Scientific Reporting
• Regulatory Affairs: Publications on FDA-related Issues – Aviva Lev-Ari, PhD, RN
• Cancer Research: Curations and Reporting
• Autobiographical Annotations: Tribute to My Professors
• Public Eulogy of Note: Prof. Allan Pred, University of California, Berkeley
• Public Eulogy of Note: Prof. David Hooson, University of California, Berkeley

 

Read Full Post »